Biography • Competition

Mr Golden is a partner at Davis Polk and for nine years was a member of its management committee. He is also a member of the board of directors of Emerson Electric, where he sits on the executive committee and chairs the corporate governance committee. He regularly represents large multinational companies with respect to acquisition-related transactions, advises clients on corporate governance matters and leads the firm's practice in competition and antitrust matters, which include domestic and international mergers and acquisitions and antitrust counselling and litigation, both private and governmental (civil and criminal).

He has also represented clients on various contested acquisition matters and numerous federal grand jury investigations, including the investigations of trading practices with respect to US government securities, the commercial tissue and explosives industries, violations of US export controls and the "Ill-Wind" criminal investigation into fraud in the Pentagon procurement process.

He acted as one of the two lead negotiators for the US tobacco industry in the effort to resolve, through legislation and settlements, the legal issues facing that industry.

Mr Golden has represented Emerson Electric in most of its significant transactions during the past three decades, including joint ventures with Caterpillar and with Robert Bosch; the acquisitions of Fisher Controls, Copeland, Daniel Industries, Vermont American, Leroy-Somer, McGill, Liebert and ASCO; and the spin-off of its defence business.

Recent representations include Roche in its acquisition of Genentech and in its hostile bid for Ventana Medical Systems; Gillette in its merger with Procter & Gamble; the directors of various mutual fund companies in investigations of that industry; Freeport-McMoRan in the criminal investigation of the copper concentrate industry; Comcast in its merger with AT&T Broadband; RJR Nabisco to Philip Morris (Kraft); Roche Holding in its previous acquisitions of Boehringer Mannheim, Syntex and Genentech and hostile bid for Sterling Drug; and Allegiance in its merger with Cardinal Health.

Litigated representations include Hoffmann-La Roche in criminal and civil antitrust litigation relating to vitamins and its recent disputes with Gilead over rights to the flu medication, Tamiflu, and with Procter & Gamble in a false advertising preliminary injunction case; AstraZeneca in various matters, including the Canadian import litigations and the brand name prescription drug antitrust litigation; Bertelsmann in the federal antitrust investigation relating to the online distribution of music; antitrust merger litigation with respect to Whirlpool's acquisition of KitchenAid; and the securities litigation in the Delaware Chancery and Supreme Courts with respect to the Fort Howard LBO.

Mr Golden is listed as a leading lawyer in several legal industry publications, including Chambers USA: America's Leading Lawyers for Business; IFLR100: The Guide to the World's Leading Financial Law Firms; Practical Law Company's Which Lawyer? , Cross-border Corporate Governance Handbook and Cross-border Competition Handbook; Law Business Research's Who's Who Legal - The International Who's Who of Corporate Governance Lawyers; Who's Who Legal - The International Who's Who of Business Lawyers; and Who's Who Legal - The International Who's Who of Competition Lawyers & Economists; and Legal Media Group's Expert Guide to the World's Leading Competition & Antitrust Lawyers and Expert Guide to the World's Leading Corporate Governance Lawyers. Davis Polk's antitrust group was also named a 'Competition Group of the Year' for 2011 by Law360.

He is also a trustee of the Rensselaer Polytechnic Institute, and has acted as director of various NYSE companies.

Mr Golden is admitted to the State of New York Bar and the US Supreme Court among others.

He obtained his BS from Rensselaer Polytechnic Institute in 1966 and his JD from New York University School of Law in 1969.